FTC Requires Fix For Aurobindo's $250M Lannett Deal
The Federal Trade Commission is allowing Aurobindo Pharma Ltd. to move ahead with its planned $250 million acquisition of Lannett Co. Inc., after the pharmaceutical company agreed to unload four generic...To view the full article, register now.
Already a subscriber? Click here to view full article